427 related articles for article (PubMed ID: 21661053)
1. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
[TBL] [Abstract][Full Text] [Related]
2. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
[TBL] [Abstract][Full Text] [Related]
3. Grasping premanifest Huntington's disease - shaping new endpoints for new trials.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Dec; 25(16):2858-62. PubMed ID: 20818671
[TBL] [Abstract][Full Text] [Related]
4. Huntington's disease: objective assessment of posture--a link between motor and functional deficits.
Reilmann R; Rumpf S; Beckmann H; Koch R; Ringelstein EB; Lange HW
Mov Disord; 2012 Apr; 27(4):555-9. PubMed ID: 22241673
[TBL] [Abstract][Full Text] [Related]
5. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease.
Hobbs NZ; Pedrick AV; Say MJ; Frost C; Dar Santos R; Coleman A; Sturrock A; Craufurd D; Stout JC; Leavitt BR; Barnes J; Tabrizi SJ; Scahill RI
Mov Disord; 2011 Aug; 26(9):1684-90. PubMed ID: 21557312
[TBL] [Abstract][Full Text] [Related]
6. Unified Huntington's disease rating scale: a follow up.
Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
[TBL] [Abstract][Full Text] [Related]
8. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease.
Aziz NA; Anguelova GV; Marinus J; Lammers GJ; Roos RA
Parkinsonism Relat Disord; 2010 Jun; 16(5):345-50. PubMed ID: 20236854
[TBL] [Abstract][Full Text] [Related]
9. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Fenney A; Jog MS; Duval C
Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of handwriting of patients with Huntington's disease.
Phillips JG; Bradshaw JL; Chiu E; Bradshaw JA
Mov Disord; 1994 Sep; 9(5):521-30. PubMed ID: 7990847
[TBL] [Abstract][Full Text] [Related]
11. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Curtis A; Mitchell I; Patel S; Ives N; Rickards H
Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the nutrition status of patients with Huntington's disease.
Trejo A; Tarrats RM; Alonso ME; Boll MC; Ochoa A; Velásquez L
Nutrition; 2004 Feb; 20(2):192-6. PubMed ID: 14962685
[TBL] [Abstract][Full Text] [Related]
13. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE
BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108
[TBL] [Abstract][Full Text] [Related]
15. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up.
van Vugt JP; Piet KK; Vink LJ; Siesling S; Zwinderman AH; Middelkoop HA; Roos RA
Mov Disord; 2004 Mar; 19(3):285-97. PubMed ID: 15022182
[TBL] [Abstract][Full Text] [Related]
16. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
17. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
[TBL] [Abstract][Full Text] [Related]
18. Factors contributing to institutionalization in patients with Huntington's disease.
Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
[TBL] [Abstract][Full Text] [Related]
19. Assessment of complex movements reflects dysfunction in Huntington's disease.
Saft C; Andrich J; Meisel NM; Przuntek H; Müller T
J Neurol; 2003 Dec; 250(12):1469-74. PubMed ID: 14673581
[TBL] [Abstract][Full Text] [Related]
20. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease.
Hart EP; Marinus J; Burgunder JM; Bentivoglio AR; Craufurd D; Reilmann R; Saft C; Roos RA;
Mov Disord; 2013 Jul; 28(8):1142-5. PubMed ID: 23495076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
